A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Alzheimer disease (AD) is characterized by amyloid beta (Abeta) aggregation and plaque deposition.
• 3-amino-1-propanesulfonic acid (3APS) is investigated as a potential disease-modifying therapy for AD.
• 3APS targets and binds to the toxic Abeta protein.

Purpose of the Study:

• To assess the safety, tolerability, and pharmacokinetics/pharmacodynamics of 3APS in AD patients.
• To evaluate the effect of 3APS on Abeta, tau, and cognitive measures.

Main Methods:

• A randomized, double-blind, placebo-controlled Phase II study.
• 58 subjects with mild-to-moderate AD received placebo or 3APS (50, 100, 150 mg BID) for 3 months.
• An open-label phase followed, with 42 subjects receiving 3APS 150 mg BID for 17 months.

Main Results:

• 3APS was safe and well-tolerated, with mild to moderate gastrointestinal side effects.
• 3APS crossed the blood-brain barrier and dose-dependently reduced CSF Abeta(42) levels.
• No significant impact on vital signs, lab values, or cognitive scores was observed during the double-blind phase.

Conclusions:

• Long-term 3APS administration is safe and tolerated in patients with mild-to-moderate AD.
• 3APS effectively reduces CSF Abeta(42) levels, indicating potential disease-modifying effects.
• Further investigation into 3APS's therapeutic efficacy for Alzheimer disease is warranted.